References
- Lawrence R. C., Helmick C. G., Arnett F. C. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998; 41: 778–799
- Hayball P. J. Chirality and nonsteroidal anti‐inflammatory drugs. Drugs 1996; 52(Suppl. 5)47–58
- Geisslinger G., Stock K. P., Bach G. L. Pharmacological differences between R(−)‐ and S(+)‐ibuprofen. Agents Actions 1992; 27: 455–457
- Laska A. Onset‐Hastened/Enhanced Analgesia. US Patent 4851444, 1987
- Leising G., Resel R. Physical aspects of dexibuprofen and racemic ibuprofen. J. Clin. Pharmacol. 1996; 36(Suppl. 12)363S–366S
- Li Z. J., Zell M. T. Characterization of racemic species of chiral drugs using thermal analysis, thermodynamic calculation, and structural studies. J. Pharm. Sci. 1998; 88: 337–346
- Kang L., Jun H. W. Preparation and characterization of two‐phase melt systems of lidocaine. Int. J. Pharm. 2002; 222: 35–44
- Kang L., Jun H. W. Formulation and efficacy studies of topical anesthetic creams. Drug Dev. Ind. Pharm. 2003; 29: 505–512
- Touitou E., Chow D. D., Lawter J. R. Chiral β‐blockers for transdermal delivery. Int. J. Pharm. 1994; 104: 19–29
- Toppo. System for Transdermal Delivery of Pain Relieving Substances. US Patent: 5,318,960, 1994
- Barry B. W. Lipid‐protein partitioning theory of skin penetration enhancement. J. Control. Release 1991; 15: 237–248
- Calpena A. C., Blanes C., Moreno J., Obach R., Domenech J. A comparative in vitro study of transdermal absorption of anti‐emetics. J. Pharm. Sci. 1994; 83: 29–33
- Kasting G. B., Smith R. L., Cooper E. R. Effects of lipid solubility and molecular size on percutaneous absorption. Pharmacol. Skin 1987; 1: 138–153